N4 Pharma (GB:N4P) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
N4 Pharma PLC has announced successful preliminary results from its collaboration with SRI International, demonstrating that their novel delivery system, Nuvec®, combined with SRI’s Fox Three Molecular Guidance System, can effectively target and knockdown specific genes. This breakthrough is a key step forward in their project, and the company plans to share more detailed findings and implications with major pharmaceutical firms. N4 Pharma’s goal is to partner with other companies, utilizing Nuvec® or Liptide® to deliver oncology, gene therapy, and vaccine products, with the prospect of earning upfront, milestone, and royalty payments.
For further insights into GB:N4P stock, check out TipRanks’ Stock Analysis page.
